<DOC>
	<DOCNO>NCT02436408</DOCNO>
	<brief_summary>Basal cell carcinoma ( BCCA ) common human cancer , frequently affect facial structure . While rarely fatal , facial BCCA disfigure expensive treat . Vismodegib small molecule inhibitor SMO develop treatment tumor Hh signal pathway appear contribute development maintenance tumorigenesis . Vismodegib recently approve Food Drug Administration ( FDA ) treatment metastatic locally advanced BCCA . Recent report suggest vismodegib treatment orbital BCCA may facilitate eye preservation even surgery eventually require In order ass potential vismodegib improve ophthalmic outcome follow treatment orbital and/or periocular BCCA , study follow patient globe-threatening orbital lacrimal-threatening periocular BCCA treat vismodegib standard care .</brief_summary>
	<brief_title>VISmodegib ORbital Periocular Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Adult patient 18 year age locally advanced recurrent orbital periorbital basal cell carcinoma ( BCCA ) , medial canthal BCCA threaten lacrimal drainage system . Clinical assessment score obtain baseline . Medical Oncology screen perform baseline . Adequate BCCA size location . Adequate hematopoietic capacity , hepatic renal function . Male patient must agree use condom treatment 2 month last dose . Male patient must agree donate sperm treatment 2 month last dose . Participant must agree donate blood study 7 month last dose . Informed consent sign . Patient must consent blood biomarker analysis . Patient must able present monthly visit duration study . Inability unwillingness swallow capsule . Inability unwillingness comply study procedure . Pregnant , lactating , breast feeding woman . Women childbearing potential . Uncontrolled medical illness . Age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>